Bupropion in the treatment of problematic online game play in patients with major depressive disorder

被引:75
|
作者
Han, Doug Hyun [2 ]
Renshaw, Perry F. [1 ]
机构
[1] Univ Utah, Inst Brain, Salt Lake City, UT 84108 USA
[2] Chung Ang Univ, Coll Med, Dept Psychiat, Seoul 156756, South Korea
关键词
Bupropion; major depressive disorder; online game play; OPEN-LABEL TRIAL; INTERNET ADDICTION; DOUBLE-BLIND; COCAINE DEPENDENCE; RELEASE BUPROPION; SUSTAINED-RELEASE; ADOLESCENTS; SYMPTOMS; ALCOHOLISM;
D O I
10.1177/0269881111400647
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As one of the problematic behaviors in patients with major depressive disorder (MDD), excessive online game play (EOP) has been reported in a number of recent studies. Bupropion has been evaluated as a potential treatment for MDD and substance dependence. We hypothesized that bupropion treatment would reduce the severity of EOP as well as depressive symptoms. Fifty male subjects with comorbid EOP and MDD were randomly assigned to bupropion + education for internet use (EDU) or placebo + EDU groups. The current study consisted in a 12-week, prospective, randomized, double-blind clinical trial, including an eight-week active treatment phase and a four-week post treatment follow-up period. During the active treatment period, Young Internet Addiction Scale (YIAS) scores and the mean time of online game playing in the bupropion group were greatly reduced compared with those of the placebo group. The Beck Depression Inventory (BDI) scores in the bupropion group were also greatly reduced compared with those of the placebo group. During the four-week post-treatment follow-up period, bupropion-associated reductions in online game play persisted, while depressive symptoms recurred. Conclusively, bupropion may improve depressive mood as well as reduce the severity of EOP in patients with comorbid MDD and online game addiction.
引用
收藏
页码:689 / 696
页数:8
相关论文
共 50 条
  • [21] Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder
    Chrzanowski, W.
    Rousseau, R.
    Hewett, K.
    Gee, M. D.
    Wightman, D.
    Richard, N. E.
    Modell, J. G.
    Goodale, E. P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S315 - S316
  • [22] Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder
    Tafseer, Sana
    Gupta, Rachna
    Ahmad, Rafat
    Jain, Seema
    Bhatia, M. S.
    Gupta, Lalit K.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2021, 200
  • [23] Agomelatine versus desvenlafaxine versus bupropion XR in the treatment of anhedonia in major depressive disorder
    Romero Guillena, S. L.
    Plasencia Garcia de Diego, B. O.
    Mata Saenz, B. O.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S461 - S462
  • [24] Effect of bupropion for nicotine dependece in patients with major depressive disorder: an open clinical trial
    Kim, H.
    Lee, K. J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S549 - S550
  • [25] Effect of bupropion for nicotine dependece in patients with major depressive disorder: an open clinical trial
    Kim, H.
    Lee, K. J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S375 - S376
  • [26] Dextromethorphan/bupropion in major depressive disorder: a profile of its use
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (08) : 270 - 278
  • [27] Bupropion - A review of its use in the management of major depressive disorder
    Dhillon, Sohita
    Yang, Lily P. H.
    Curran, Monique P.
    DRUGS, 2008, 68 (05) : 653 - 689
  • [28] Dextromethorphan/bupropion in major depressive disorder: a profile of its use
    Hannah A. Blair
    Drugs & Therapy Perspectives, 2023, 39 : 270 - 278
  • [29] Effect of a Major Depressive Disorder History and of Bupropion Treatment on Smoking-Induced Dopamine Release
    Brody, Arthur
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 187S - 187S
  • [30] Pharmacological treatment for insomnia in patients with major depressive disorder
    Brietzke, Elisa
    Vazquez, Gustavo H.
    Kang, Melody J. Y.
    Soares, Claudio N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (11) : 1341 - 1349